Embolic Microspheres

Embolic Microspheres Market Outlook

The global embolic microspheres market is projected to reach approximately USD 6.1 billion by 2035, growing at a compound annual growth rate (CAGR) of 11.2% from 2025 to 2035. This growth can be attributed to the rising incidence of various cancers, particularly liver cancer, and the increasing acceptance of minimally invasive procedures among healthcare providers and patients alike. Furthermore, the technological advancements in microsphere manufacturing and the growing geriatric population are also significant factors contributing to market expansion. As healthcare continues to evolve, there are increasing investments in R&D for innovative therapeutic techniques, which are anticipated to bolster the demand for embolic microspheres in the coming years.

Growth Factor of the Market

One of the critical growth factors driving the embolic microspheres market is the escalating prevalence of cancer and vascular diseases globally. This trend has resulted in a rising demand for effective therapeutic solutions such as embolization procedures that utilize microspheres for targeted drug delivery and tumor vascular occlusion. Additionally, the minimally invasive nature of embolic microsphere procedures has led to shorter recovery times and reduced hospital stays, making them increasingly preferred by both healthcare professionals and patients. The technological advancements in imaging techniques and the development of new formulations of microspheres further enhance the efficacy of these procedures, supporting patient safety and improving clinical outcomes. Moreover, the growing investment in healthcare infrastructure, particularly in emerging economies, is poised to provide ample opportunities for market expansion. The increased awareness of the benefits of embolization therapy, along with favorable reimbursement policies, is also expected to propel market growth in the foreseeable future.

Key Highlights of the Market

• Projected global market size of around USD 6.1 billion by 2035.
• CAGR expected to be 11.2% from 2025 to 2035.
• Rising incidence of cancers such as liver cancer driving demand.
• Technological advancements in embolization techniques.
• Growing acceptance of minimally invasive procedures.

By Product Type

Radio-Embolic Microspheres:

Radio-embolic microspheres are a specific category that combines the benefits of embolization with radiotherapy. These microspheres are often used for treating liver tumors, where they deliver localized radiation directly to the tumor site while simultaneously blocking blood flow. The dual-action approach improves treatment efficacy and minimizes damage to surrounding healthy tissues. Their effectiveness in targeted therapy makes them a popular choice among oncologists, and continuous advancements in the development of these microspheres are expected to enhance their application further, thus driving market growth.

Drug-Eluting Microspheres:

Drug-eluting microspheres are designed for controlled and localized release of therapeutic agents over an extended period. They are particularly effective in the treatment of various malignancies, offering a significant advantage in minimizing systemic side effects associated with traditional chemotherapy. The tailored formulation allows for direct targeting of tumor sites, enhancing the therapeutic effects while reducing the frequency of administration. As research on drug-eluting technologies progresses, the ability to combine chemotherapeutic agents with microspheres is anticipated to expand treatment options, thus driving their adoption in the embolic microspheres market.

Biodegradable Microspheres:

Biodegradable microspheres are increasingly gaining traction in the embolic microspheres market because of their ability to break down in the body over time. This property eliminates the need for subsequent removal procedures, making them a more patient-friendly option. They are often used in various embolization procedures for conditions such as uterine fibroids and liver cancer, where they effectively occlude blood vessels. The continuous R&D efforts focused on improving the degradation rates and drug release profiles of these microspheres are expected to propel their application, thereby contributing to market growth.

Non-Biodegradable Microspheres:

Non-biodegradable microspheres are designed for applications where prolonged occlusion is required. They are often employed in procedures involving permanent vascular occlusion, such as in the treatment of liver tumors or varicose veins. While they do not dissolve in the body, their effectiveness in achieving permanent occlusion makes them indispensable in certain medical procedures. The ongoing advancements in materials and techniques used to manufacture these microspheres are set to enhance their efficacy and safety profiles, thereby ensuring their continued demand in the embolic microspheres market.

Metallic Microspheres:

Metallic microspheres, often composed of materials such as iron or gold, are utilized for their unique properties, including radiopacity and the ability to carry drugs. They are increasingly being explored for their potential in enhanced imaging and targeted therapy. The incorporation of metallic microspheres in procedures allows for precise visualization during embolization interventions and, when combined with therapeutic agents, can improve treatment outcomes. As medical technology advances, the application of metallic microspheres in both diagnostic and therapeutic settings is expected to expand significantly, contributing to the overall growth of the embolic microspheres market.

By Application

Liver Cancer:

Liver cancer is one of the leading applications for embolic microspheres due to the rising incidence of hepatocellular carcinoma and liver metastases. The use of embolic microspheres in transarterial chemoembolization (TACE) procedures allows for targeted delivery of chemotherapeutic agents directly to the tumor while simultaneously occluding blood supply to the cancerous tissue. This method not only improves the concentration of the drug at the tumor site but also minimizes systemic exposure, significantly enhancing patient outcomes. With the increasing focus on innovative treatments for liver cancer, the demand for embolic microspheres in this application is expected to witness substantial growth in the coming years.

Uterine Fibroids:

Embolic microspheres are widely used in the management of uterine fibroids through a procedure known as uterine artery embolization (UAE). This minimally invasive technique involves the injection of microspheres into the uterine arteries to block blood flow to the fibroids, leading to their shrinkage and alleviation of associated symptoms. The rising awareness of UAE as a viable alternative to surgical interventions, along with its effectiveness in treating symptomatic fibroids, is driving the growth of embolic microspheres in this application. As more patients seek less invasive treatment options, the market for embolic microspheres for uterine fibroids is anticipated to expand significantly.

Prostate Artery Embolization:

Prostate artery embolization (PAE) is emerging as a promising treatment for benign prostatic hyperplasia (BPH) and an enlarged prostate. The use of embolic microspheres in this procedure allows for the selective occlusion of blood vessels supplying the prostate, leading to a reduction in its size and associated symptoms. As an alternative to surgical methods, PAE has gained popularity due to its minimally invasive nature and quick recovery time. The increasing prevalence of BPH among the aging male population is expected to further propel the adoption of embolic microspheres in this application.

Peripheral Vascular Disease:

Peripheral vascular disease (PVD) is another significant application area for embolic microspheres. In the context of PVD, microspheres are utilized to occlude diseased or blocked arteries, improving circulation and alleviating symptoms associated with the condition. The rising incidence of PVD, coupled with the growing awareness of advanced treatment options, is anticipated to drive the demand for embolic microspheres in this application segment. Furthermore, ongoing innovations in this domain are expected to enhance the effectiveness of these microspheres, contributing positively to market growth.

Others:

The "Others" segment captures additional applications of embolic microspheres, including their use in treating conditions such as gastrointestinal bleeding and renal tumors. The versatility of microsphere technology allows for customized formulations tailored to specific therapeutic needs, making them suitable for a wide range of interventions. As research continues to unveil new applications and benefits of embolic microspheres, this segment is expected to grow alongside the more established applications, contributing to the overall market expansion.

By Distribution Channel

Hospitals:

Hospitals remain the primary distribution channel for embolic microspheres, accounting for a substantial share of the market. The established infrastructure, availability of trained healthcare professionals, and advanced facilities in hospitals contribute significantly to the high volume of embolization procedures performed in these settings. Additionally, hospitals often have access to the latest technology and innovations, ensuring that patients receive the most effective treatments. The increasing number of procedures performed in hospitals, along with favorable reimbursement policies, is expected to support the growth of this distribution channel.

Ambulatory Surgical Centers:

Ambulatory surgical centers (ASCs) are gaining prominence as alternative distribution channels for embolic microspheres. These centers provide a more convenient and cost-effective environment for patients undergoing minimally invasive procedures. The rising trend toward outpatient care, coupled with advancements in embolization techniques, has led to an increase in the number of procedures being performed in ASCs. The growing acceptance of ASCs by patients and healthcare providers as viable options for certain procedures is expected to further enhance the demand for embolic microspheres in this channel.

Specialty Clinics:

Specialty clinics, particularly those focused on interventional radiology, oncology, and vascular surgery, are playing an increasingly important role in the distribution of embolic microspheres. These clinics offer targeted expertise and state-of-the-art facilities for performing complex procedures, making them a preferred choice for patients requiring specialized care. The growth of specialty clinics is driven by the rising demand for minimally invasive treatment options and the increasing focus on patient-centric care. As the number of specialty clinics continues to rise, their contribution to the embolic microspheres market is expected to grow significantly.

Online Sales:

Online sales channels are gradually emerging as a distribution strategy for embolic microspheres, particularly for medical professionals and facilities looking for convenience and efficiency in procurement. This approach allows healthcare providers to access a broader range of products and technologies without the limitations of geographical boundaries. Additionally, online platforms often provide comprehensive product information, enabling informed decision-making. The ongoing digital transformation in healthcare and the growing reliance on e-commerce are anticipated to push the adoption of online sales channels in the embolic microspheres market.

Others:

The "Others" segment includes various distribution channels such as medical supply distributors and direct sales by manufacturers. These channels play a crucial role in ensuring the availability of embolic microspheres to hospitals, ASCs, and specialty clinics. The relationships between manufacturers and distributors are essential for maintaining a steady supply chain, which significantly impacts the overall market dynamics. As the demand for embolic microspheres continues to grow, the effectiveness and efficiency of these distribution channels will become increasingly important to meet the evolving needs of healthcare providers.

By Ingredient Type

Polyvinyl Alcohol:

Polyvinyl alcohol (PVA) is a widely used ingredient in the formulation of embolic microspheres due to its biocompatibility and ability to form stable microspheres. PVA-based microspheres are particularly effective for use in transarterial embolization procedures, where they provide optimal occlusion of blood vessels while minimizing adverse effects. The versatility of PVA allows for modifications in its properties, enabling the development of microspheres tailored to specific therapeutic applications. As a result, the demand for PVA-based embolic microspheres is expected to grow steadily within the market.

Hydrogel Microspheres:

Hydrogel microspheres are gaining attention for their unique properties, including high water content and flexibility, which contribute to their effectiveness in various embolization procedures. These microspheres can encapsulate drugs, allowing for controlled release and localized therapy. Their biocompatibility makes them suitable for a range of applications, from oncology to vascular interventions. The potential for tailoring hydrogel microspheres to enhance drug delivery systems positions them as a promising ingredient type within the embolic microspheres market, and their adoption is anticipated to increase in the coming years.

Glass Microspheres:

Glass microspheres are characterized by their durability and radiopacity, making them ideal for use in a variety of embolization procedures. Their inert nature and consistent size distribution allow for predictable occlusion of blood vessels, enhancing treatment efficacy. Utilization of glass microspheres can result in improved imaging during procedures, giving healthcare providers better visualization during embolization. The unique properties of glass microspheres are driving their popularity in the embolic microspheres market, and ongoing advancements in glass microsphere technology are expected to further bolster their use.

Polymeric Microspheres:

Polymeric microspheres are constructed from biodegradable or non-biodegradable polymers and are increasingly used in embolization procedures due to their tailored properties. These microspheres can be designed to release drugs in a controlled manner, enhancing therapeutic effectiveness while reducing side effects. The capacity to customize polymeric microspheres for specific applications, combined with ongoing research and development efforts, is expected to drive their adoption within the embolic microspheres market. The versatility of polymeric microspheres ensures their continued relevance as the market evolves.

Drug-Eluting Agents:

Drug-eluting agents integrated into microspheres represent a significant advancement in embolization therapies. These agents allow for the localized delivery of chemotherapeutic drugs directly to the tumor site, maximizing treatment efficacy while minimizing systemic exposure. The ongoing research into various drug-eluting formulations and their combinations with embolic microspheres is expected to expand the range of applications and improve patient outcomes. As more healthcare providers recognize the benefits of drug-eluting microspheres, their demand is projected to increase within the embolic microspheres market.

By Region

The embolic microspheres market exhibits regional variation, with North America holding a dominant position, valued at approximately USD 2.3 billion in 2025. The high prevalence of cancer in this region, coupled with the growing number of minimally invasive procedures performed, has led to significant adoption of embolic microspheres. Moreover, the presence of advanced healthcare infrastructure and continuous innovations in embolization technologies contribute to the sustained growth of the market in North America. The region is expected to grow at a CAGR of 10.5% through to 2035, further solidifying its position as a leading market for embolic microspheres.

Europe is another key region in the embolic microspheres market, valued at approximately USD 1.6 billion in 2025. The increasing number of patients seeking advanced cancer treatments and the rising awareness of the benefits of embolization procedures are driving market expansion in this region. Additionally, the growing focus on enhancing healthcare systems and improving patient outcomes is expected to support the growth of embolic microspheres in European countries. The market in Asia Pacific is also witnessing significant growth due to rising investments in healthcare infrastructure and increasing incidences of vascular diseases and cancers, indicating a promising future for embolic microspheres across various regions.

Opportunities

The embolic microspheres market is poised to witness numerous opportunities driven by advancements in medical technology and a growing understanding of the benefits of embolization therapies. One significant opportunity lies in the ongoing research and development focused on creating more effective and targeted embolic agents. Innovations in material science and drug delivery systems can lead to the development of new types of microspheres that can offer improved therapeutic outcomes and patient safety. The growing trend of personalized medicine is also anticipated to create opportunities for creating customized microspheres tailored to individual patient requirements, enhancing the effectiveness of treatments and improving overall satisfaction.

Moreover, the increasing investments in healthcare infrastructure, particularly in emerging economies, present lucrative opportunities for the embolic microspheres market. As these regions continue to develop their healthcare systems, there will be a rising demand for advanced medical interventions, including embolization procedures. Furthermore, partnerships between manufacturers and healthcare providers can foster the introduction of innovative products and techniques, broadening the applications of embolic microspheres within various medical fields. This collaborative approach will not only enhance the overall market potential for embolic microspheres but also improve patient outcomes and quality of care significantly.

Threats

Despite the growth potential, the embolic microspheres market faces several threats that could challenge its expansion. One of the primary concerns is the stringent regulatory environment governing medical devices and pharmaceuticals. The lengthy approval process for new embolic products can hinder timely access to innovative therapies, ultimately affecting market dynamics. Additionally, the increasing competition among various manufacturers can lead to price wars, which may undermine profit margins and impact the financial viability of smaller companies. Furthermore, the rising incidence of hospital-acquired infections and complications associated with embolization procedures can cause reluctance among patients and healthcare providers to adopt these techniques, posing a significant threat to market growth.

Another threat to the embolic microspheres market is the availability of alternative treatment options for conditions typically treated with embolization. For instance, ongoing advancements in systemic therapies, including immunotherapy and targeted therapies, may overshadow the demand for embolization procedures. Patients may opt for these newer therapies due to their promising results, which could lead to a decline in the utilization of embolic microspheres. Addressing these challenges will require continuous innovation, effective marketing strategies, and collaborations within the healthcare sector to ensure that embolic microspheres remain a preferred choice for treating various medical conditions.

Competitor Outlook

• Merit Medical Systems, Inc.
• Boston Scientific Corporation
• Terumo Corporation
• Cook Medical
• Johnson & Johnson
• Medtronic plc
• Stryker Corporation
• Guerbet
• AngioDynamics, Inc.
• Biocompatibles UK Ltd. (a BTG International group company)
• Abbot Laboratories
• OncoOne
• Solvay S.A.
• Halyard Health, Inc.
• W. L. Gore & Associates, Inc.

The competitive landscape of the embolic microspheres market is characterized by a diverse range of companies, each vying for market share through innovative product offerings and strategic alliances. Established players like Merit Medical Systems, Inc. and Boston Scientific Corporation lead the market due to their extensive portfolios and innovative technologies. These organizations leverage their R&D capabilities to develop new embolic agents and improve existing products, thereby gaining a competitive edge. Furthermore, collaborations and partnerships among these companies foster the sharing of knowledge and resources, leading to the introduction of cutting-edge embolic microsphere technologies in the market.

In addition to established players, several emerging companies are entering the embolic microspheres market, focusing on niche applications and novel formulations. Companies like OncoOne are dedicated to developing specialized embolic solutions targeting specific cancers, while others such as Guerbet and AngioDynamics emphasize expanding their product offerings to cater to various medical applications. The presence of these emerging players contributes to the overall competitiveness of the market, encouraging continuous innovation and diversification of products available to healthcare providers.

Another key aspect of the competitive landscape is the ongoing trend of mergers and acquisitions, allowing companies to enhance their product portfolios and expand their market reach. For instance, larger corporations may acquire smaller firms with innovative technologies, gaining access to new products and expertise. This strategy not only facilitates market expansion but also fosters collaboration and knowledge transfer among companies, ultimately benefiting the embolic microspheres market as a whole. The competitive dynamics are expected to remain robust as companies continue to innovate and respond to evolving market demands.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Guerbet
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 OncoOne
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Solvay S.A.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Cook Medical
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Medtronic plc
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Johnson & Johnson
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Abbot Laboratories
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Terumo Corporation
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 AngioDynamics, Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Stryker Corporation
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Halyard Health, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Merit Medical Systems, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Boston Scientific Corporation
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 W. L. Gore & Associates, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Biocompatibles UK Ltd. (a BTG International group company)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Embolic Microspheres Market, By Application
    • 6.1.1 Liver Cancer
    • 6.1.2 Uterine Fibroids
    • 6.1.3 Prostate Artery Embolization
    • 6.1.4 Peripheral Vascular Disease
    • 6.1.5 Others
  • 6.2 Embolic Microspheres Market, By Product Type
    • 6.2.1 Radio-Embolic Microspheres
    • 6.2.2 Drug-Eluting Microspheres
    • 6.2.3 Biodegradable Microspheres
    • 6.2.4 Non-Biodegradable Microspheres
    • 6.2.5 Metallic Microspheres
  • 6.3 Embolic Microspheres Market, By Ingredient Type
    • 6.3.1 Polyvinyl Alcohol
    • 6.3.2 Hydrogel Microspheres
    • 6.3.3 Glass Microspheres
    • 6.3.4 Polymeric Microspheres
    • 6.3.5 Drug-Eluting Agents
  • 6.4 Embolic Microspheres Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Ambulatory Surgical Centers
    • 6.4.3 Specialty Clinics
    • 6.4.4 Online Sales
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Embolic Microspheres Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Embolic Microspheres market is categorized based on

By Product Type

• Radio-Embolic Microspheres
• Drug-Eluting Microspheres
• Biodegradable Microspheres
• Non-Biodegradable Microspheres
• Metallic Microspheres

By Application

• Liver Cancer
• Uterine Fibroids
• Prostate Artery Embolization
• Peripheral Vascular Disease
• Others

By Distribution Channel

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
• Online Sales
• Others

By Ingredient Type

• Polyvinyl Alcohol
• Hydrogel Microspheres
• Glass Microspheres
• Polymeric Microspheres
• Drug-Eluting Agents

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Merit Medical Systems, Inc.
• Boston Scientific Corporation
• Terumo Corporation
• Cook Medical
• Johnson & Johnson
• Medtronic plc
• Stryker Corporation
• Guerbet
• AngioDynamics, Inc.
• Biocompatibles UK Ltd. (a BTG International group company)
• Abbot Laboratories
• OncoOne
• Solvay S.A.
• Halyard Health, Inc.
• W. L. Gore & Associates, Inc.